TriangleNCT02711345 · OUTCOME
Progression Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years)
What was measured
Median time for progression free survival was reported.
Analysis population: The full analysis set included all participants who had received at least one dose of LTT462.
Groups in this outcome
LTT462 45 mg QD
Participants received 45 mg LTT462 QD as oral capsules.
LTT462 100 mg QD
Participants received 100 mg LTT462 QD as oral capsules.
LTT462 150 mg QD
Participants received 150 mg LTT462 QD as oral capsules.
LTT462 200 mg QD
Participants received 200 mg LTT462 QD as oral capsules.
LTT462 300 mg QD
Participants received 300 mg LTT462 QD as oral capsules.
LTT462 400 mg QD
Participants received 400 mg LTT462 QD as oral capsules.
LTT462 450 mg QD
Participants received 450 mg LTT462 QD as oral capsules.
LTT462 600 mg QD
Participants received 600 mg LTT462 QD as oral capsules.
LTT462 150 mg BID
Participants received 150 mg LTT462 twice daily (BID) as oral capsules
LTT462 200 mg BID
Participants received 200 mg LTT462 BID as oral capsules.
| Group | Source count |
|---|---|
| LTT462 45 mg QD | 2 |
| LTT462 100 mg QD | 3 |
| LTT462 150 mg QD | 6 |
| LTT462 200 mg QD | 4 |
| LTT462 300 mg QD | 8 |
| LTT462 400 mg QD | 6 |
| LTT462 450 mg QD | 12 |
| LTT462 600 mg QD | 6 |
| LTT462 150 mg BID | 6 |
| LTT462 200 mg BID | 12 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| LTT462 45 mg QD | 5.3 | Not reported | 1.3 | 9.2 | Not reported |
| LTT462 100 mg QD | 1.6 | Not reported | 0.9 | 1.7 | Not reported |
| LTT462 150 mg QD | 1.7 | Not reported | 1.2 | 2.0 | Not reported |
| LTT462 200 mg QD | 1.9 | Not reported | 1.7 | 1.9 | Not reported |
| LTT462 300 mg QD | 1.8 | Not reported | 1.2 | 5.1 | Not reported |
| LTT462 400 mg QD | 2.1 | Not reported | 0.8 | 3.2 | Not reported |
| LTT462 450 mg QD | 0.9 | Not reported | 0.8 | 1.6 | Not reported |
| LTT462 600 mg QD | 1.4 | Not reported | 0.7 | 4.0 | Not reported |
| LTT462 150 mg BID | 1.5 | Not reported | 1.2 | 3.7 | Not reported |
| LTT462 200 mg BID | 1.6 | Not reported | 0.8 | 1.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.3
- upper Limit
- 9.2
- value
- 5.3
- group Id
- OG001
- lower Limit
- 0.9
- upper Limit
- 1.7
- value
- 1.6
- group Id
- OG002
- lower Limit
- 1.2
- upper Limit
- 2.0
- value
- 1.7
- group Id
- OG003
- lower Limit
- 1.7
- upper Limit
- 1.9
- value
- 1.9
- group Id
- OG004
- lower Limit
- 1.2
- upper Limit
- 5.1
- value
- 1.8
- group Id
- OG005
- lower Limit
- 0.8
- upper Limit
- 3.2
- value
- 2.1
- group Id
- OG006
- lower Limit
- 0.8
- upper Limit
- 1.6
- value
- 0.9
- group Id
- OG007
- lower Limit
- 0.7
- upper Limit
- 4.0
- value
- 1.4
- group Id
- OG008
- lower Limit
- 1.2
- upper Limit
- 3.7
- value
- 1.5
- group Id
- OG009
- lower Limit
- 0.8
- upper Limit
- 1.7
- value
- 1.6
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 6
- group Id
- OG003
- value
- 4
- group Id
- OG004
- value
- 8
- group Id
- OG005
- value
- 6
- group Id
- OG006
- value
- 12
- group Id
- OG007
- value
- 6
- group Id
- OG008
- value
- 6
- group Id
- OG009
- value
- 12
- units
- Participants
- description
- Median time for progression free survival was reported.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received 45 mg LTT462 QD as oral capsules.
- id
- OG000
- title
- LTT462 45 mg QD
- description
- Participants received 100 mg LTT462 QD as oral capsules.
- id
- OG001
- title
- LTT462 100 mg QD
- description
- Participants received 150 mg LTT462 QD as oral capsules.
- id
- OG002
- title
- LTT462 150 mg QD
- description
- Participants received 200 mg LTT462 QD as oral capsules.
- id
- OG003
- title
- LTT462 200 mg QD
- description
- Participants received 300 mg LTT462 QD as oral capsules.
- id
- OG004
- title
- LTT462 300 mg QD
- description
- Participants received 400 mg LTT462 QD as oral capsules.
- id
- OG005
- title
- LTT462 400 mg QD
- description
- Participants received 450 mg LTT462 QD as oral capsules.
- id
- OG006
- title
- LTT462 450 mg QD
- description
- Participants received 600 mg LTT462 QD as oral capsules.
- id
- OG007
- title
- LTT462 600 mg QD
- description
- Participants received 150 mg LTT462 twice daily (BID) as oral capsules
- id
- OG008
- title
- LTT462 150 mg BID
- description
- Participants received 200 mg LTT462 BID as oral capsules.
- id
- OG009
- title
- LTT462 200 mg BID
- param Type
- MEDIAN
- population Description
- The full analysis set included all participants who had received at least one dose of LTT462.
- reporting Status
- POSTED
- time Frame
- Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years)
- title
- Progression Free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice